BIO Praises the Release of the 21st Century Cures Initiative Discussion Draft
![](/46/pdcnewsitem/03/41/17/1kjBX50qxZIxBlN.png)
The Biotechnology Industry Organization (BIO) has released the following statement on the 21st Century Cures Initiative discussion draft shared by Chairman Fred Upton (R-MI).
Jim Greenwood, BIO President and CEO said: “Today, we recognise and thank the Committee on Energy and Commerce for releasing its 21st Century Cures Initiative discussion draft intended to accelerate the discovery, development and delivery of next-generation modern medicines to transform patient care.
“Working with member companies, patient advocacy groups, and other stakeholders, we developed numerous proposals to create a public policy environment that encourages the use of 21st century scientific tools, advancements in molecular biology, and novel bioinformatics to continuously develop and improve upon therapies that can prevent, diagnose and treat all stages of disease.
“We are pleased to see several of our priority suggestions in the discussion draft, including the need for a large-scale national research commitment to study precursors and signs of disease and disease risk factors for chronic conditions. Through the 21st Century Cures Initiative, we hope to work with the Congress, the NIH, and the patient community to develop a study that has the potential to revolutionize our understanding of disease, thus resulting in better treatments and cures.
“We also embrace the focus on precision medicine through genomics and regulatory science. Industrial-scale biomarker qualification and full genome sequencing will help us better understand the molecular basis of disease and develop precision therapies tailored to each patient.
“We believe that placing patients at the center of the drug development process will spur the development of therapies for the most prevalent conditions, as well as encourage development of treatments focused on unmet medical needs. We strongly support establishing a framework for incorporating patient views into the development and regulatory review process in a more structured and transparent way, with respect to benefit-risk assessments and use of patient experience data.
“Further, we support modernising clinical trials to expedite and accelerate drug development through the use of alternative clinical trial designs, biomarkers and surrogate endpoints, and modern scientific approaches and greater utilization of post-market validation and other confirmatory techniques, including the use of real-world data.
“We also strongly support provisions intended to further incentivize biomedical innovation and help expedite the development of new treatments and cures, particularly in areas of unmet medical need where existing incentives may be inadequate to drive sufficient investment.
“In addition, we support enhancing the FDA’s scientific capacity by improving access to adequate funding, recruiting world-class scientific and technical experts, and expanding management processes and human resource functions to meet the complexities of 21st Century scientific discovery.
“While we are still reviewing the many proposals contained within the discussion draft, we look forward to working with Chairman Upton and Rep. DeGette to ensure that the 21st Century Cures Initiative expedites the delivery of the next generation of modern medicines that will save lives and reduce and eliminate suffering.”
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance